Condition: Prostatic Neoplasm · Adenocarcinoma · Neoplasm Recurrence · Sponsor: Centre Hospitalier Universitaire de la Guadeloupe
The course and progression of prostate cancer is highly variable, depending on the individual characteristics, the aggressiveness of the disease at the time of diagnosis as well as the ethno-geographic origins of the individuals. The general objective of the project is to identify the clinical, genetic and environmental determinants (risk factors) of the evolution, progression and complications of the disease according to the treatment options. Identifying modifiable and non-modifiable prognostic determinants of disease progression is a major challenge. This knowledge will help guide treatment choices but also, especially in high-risk populations (high incidence of disease) to better tailor prevention policies and possibly screening .
This description comes directly from the study's public registry record.
Valérie HAMONY-SOTER · +590 590 93 46 77 · valerie.soter@chu-guadeloupe.fr
Eunice NUBRET · +590 590 93 46 86 · eunice.nubret@chu-guadeloupe.fr
Always discuss trial participation with your own doctor first.
| CHU of Rennes | Rennes, Ille-et-Vilaine, France | Not Yet Recruiting |
| CHU of Guadeloupe | Pointe-à-Pitre, Guadeloupe, Guadeloupe | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06046131